Dupixent (dupilumab) is generally well tolerated, but its most serious side effects include severe allergic reactions, eye inflammation that can affect vision, and rare eosinophilic conditions that can damage blood vessels or lungs. In a five-year study of over 2,600 adults with atopic dermatitis, about 10% experienced at least one serious side effect, and 3.8% had a reaction severe enough to stop treatment permanently. Most people do well on Dupixent, but the side effects worth watching for range from common nuisances to rare complications that need prompt attention.
Severe Allergic Reactions
The most dangerous potential side effect is anaphylaxis, a whole-body allergic reaction that can cause breathing difficulty, a rapid drop in blood pressure, and swelling of the throat. This is rare, but it’s listed as a formal FDA warning. Other hypersensitivity reactions include serum sickness (a delayed immune response causing fever, joint pain, and rash), angioedema (deep swelling under the skin, often around the face), and widespread hives. Any of these reactions typically means Dupixent needs to be stopped.
Eye Problems: Conjunctivitis and Keratitis
Eye inflammation is Dupixent’s signature side effect and the one that surprises most patients. Conjunctivitis (pink eye) is the most common ocular issue, occurring at notably higher rates in people on Dupixent than in those on placebo. In pediatric studies, conjunctivitis affected about 9% of children on Dupixent compared to 7% of those not taking it, and atopic conjunctivitis specifically was about 50% more likely in the treatment group.
Keratitis, which is inflammation of the cornea itself, is rarer but more concerning because it can affect vision. Studies have found a threefold increased risk of keratitis in patients taking Dupixent. Symptoms include eye redness, pain, light sensitivity, blurred vision, and a gritty or burning sensation. In the five-year safety study, conjunctivitis was the specific side effect that led to permanent discontinuation most often, accounting for 0.4% of all patients.
Why Dupixent causes eye problems isn’t fully understood. The drug works by blocking two immune signaling molecules, IL-4 and IL-13, which helps calm the overactive inflammation behind eczema and asthma. But those same molecules appear to play a protective role on the surface of the eye. Blocking them may disrupt tear production, reduce protective cells in the eye’s outer lining, or allow other inflammatory pathways to take over. Impaired tear drainage has also been linked to the problem in some patients.
Eosinophilic Conditions
Eosinophils are a type of white blood cell involved in allergic responses. Dupixent can cause eosinophil levels to rise, and in rare cases this leads to serious complications. The two most concerning are eosinophilic pneumonia, where eosinophils accumulate in the lungs and cause breathing difficulty, and eosinophilic granulomatosis with polyangiitis (EGPA), a form of blood vessel inflammation that can affect the lungs, skin, nerves, and heart.
EGPA has been reported in patients taking Dupixent for severe asthma, including two cases identified during major phase 3 clinical trials. In one published case, a patient developed widespread lung bleeding and blood vessel inflammation with dangerously high eosinophil counts despite being on high-dose steroids. The risk appears particularly tied to situations where patients are tapering off oral corticosteroids while on Dupixent. Reducing steroids can “unmask” an underlying eosinophilic condition that the steroids were keeping in check. Warning signs include worsening breathing, a rash that looks like bruising or small spots on the skin, fever, chest pain, and numbness or tingling in the hands and feet.
New-Onset Joint Pain
Joint pain and stiffness is an increasingly recognized side effect. In clinical trials for nasal polyps and eosinophilic esophagitis, arthralgia was common enough to make the official adverse reaction list. But case reports paint a more detailed picture: patients have developed bilateral hand and finger joint pain with visible swelling, shoulder stiffness, and generalized joint aches anywhere from 2 to 11 months after starting treatment.
Some patients have gone on to develop psoriatic arthritis requiring its own treatment. In documented cases, joint symptoms improved only after Dupixent was discontinued, and rheumatology evaluations in at least two patients came back without any other explanation for the pain. This side effect can be particularly frustrating because Dupixent is otherwise working well for the condition it was prescribed for.
New-Onset Psoriasis
Dupixent can paradoxically trigger psoriasis, a different inflammatory skin condition, even though it’s prescribed to treat skin inflammation. This is listed as a formal FDA warning. Patients with atopic dermatitis and asthma seem most susceptible. The psoriasis can appear as thick, scaly patches in areas where the eczema has cleared, which can be confusing. If symptoms persist or worsen, stopping Dupixent may be necessary.
Injection Site Reactions
About 10% of patients experience reactions at the injection site, compared to 5-6% of those receiving placebo injections. These typically involve redness, swelling, itching, or pain where the needle went in. While not dangerous, they’re the single most common side effect and can be persistent enough to affect quality of life over months of treatment. Most are mild to moderate and tend to improve with continued use.
Infections and Immune Effects
Because Dupixent modifies part of the immune system, it affects the body’s ability to fight certain infections. Oral herpes and other herpes simplex virus infections occur more frequently in patients on Dupixent. Upper respiratory infections are also commonly reported, particularly in patients being treated for eosinophilic esophagitis.
Dupixent also suppresses the immune pathway needed to fight parasitic worm infections. If you have an existing parasitic infection, it needs to be treated before starting Dupixent, because the drug can allow the infection to persist or worsen even with anti-parasitic medication. Live vaccines are also off-limits during treatment, since the altered immune response could allow a live vaccine virus to cause actual illness rather than building immunity.
Long-Term Safety Profile
Five-year data from over 2,600 adults with atopic dermatitis offers some reassurance. The rate of side effects actually decreased over time: patients experienced fewer adverse events per year in the long-term extension study than in the original 52-week trial. Infection rates were also lower among patients on Dupixent long-term (70.7 per 100 patient-years) compared to both the Dupixent arm (93.7) and placebo arm (107.0) of the earlier controlled trial.
Over the full five years, 10.6% of patients had at least one serious side effect, 10% had at least one severe side effect, and only 1.2% had a serious side effect that was judged to be directly related to the drug. The 3.8% permanent discontinuation rate is relatively low for a long-term biologic medication, suggesting that most patients who tolerate Dupixent initially continue to tolerate it well.